Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alice T. Shaw"'
Autor:
Ben Solomon, D-W. Kim, Enriqueta Felip, D.S-W. Tan, Lilli Petruzzelli, Sebastian Szpakowski, Michael Thomas, Laura Q.M. Chow, Johan Vansteenkiste, Alice T. Shaw, Serafino Pantano, Patrick Urban, Ranee Mehra, D.R. Camidge, Sunil Sharma
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 163
Objectives To better understand genetic determinants of response to ceritinib, an exploratory analysis was conducted using tumor biopsies from anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non–small-cell lung cancer (NSCLC) patients treated wi
Autor:
Elizabeth T. Masters, Benjamin Besse, Antonello Abbattista, Alice T. Shaw, D. Ross Camidge, Shirish M. Gadgeel, Gerson Peltz, Holger Thurm, Takashi Seto, Benjamin Solomon, Enriqueta Felip, Chia-Chi Lin, Solange Peters, Jill S. Clancy, Arlene Reisman, Ross A. Soo, Steven Kao, Alessandra Bearz
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 144
Objectives To evaluate patient-reported outcomes (PROs) from a phase 1/2 study (NCT01970865) in patients with anaplastic lymphoma kinase (ALK)- or ROS1-positive advanced non-small cell lung cancer (NSCLC) treated with lorlatinib 100 mg once daily. Ma
Autor:
Tianqi Chen, Alice T. Shaw, Jo-Anne O. Shepard, Subba R. Digumarthy, Dexter P. Mendoza, Ibiayi Dagogo-Jack, Atul Padole
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 129
Objectives Mutations in the BRAF gene have emerged as a validated molecular target in the treatment of non-small cell lung cancer (NSCLC). These mutations can be classified into three functional classes based on their mechanisms of oncogenesis. The r
Autor:
Mark G. Kris, Juliana Eng, Benjamin Izar, Emily Chin, Justin F. Gainor, Fernando C. Santini, David R. Jones, Jamie E. Chaft, Ibiayi Dagogo-Jack, Alice T. Shaw, Beow Y. Yeap
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 122
Objectives Reports of the prognostic significance of ALK-rearrangement in resected non-small cell lung cancer (NSCLC) have been contradictory. We aimed to determine the prognosis of early-stage ALK-positive lung cancers relative to KRAS- and EGFR-mut